Cost-Effectiveness in the Surgical Care of Renal Cell Carcinoma

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2018年 / 16卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：177 / 179
页数：3
相关论文
共 50 条
  • [1] Cost-effectiveness of sunitinib in metastatic renal cell carcinoma
    Purmonen, Timo T.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2011, 11 (04) : 383 - 393
  • [2] Cost-effectiveness of nivolumab in advanced renal cell carcinoma.
    Sarfaty, Michal
    Leshno, Moshe
    Gordon, Noa
    Moore, Assaf
    Neiman, Victoria
    Rosenbaum, Eli
    Goldstein, Daniel A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] COST-EFFECTIVENESS OF TIVOZANIB IN ADVANCED RENAL CELL CARCINOMA IN THE US
    Ta, R.
    VALUE IN HEALTH, 2024, 27 (06) : S73 - S73
  • [4] COST-EFFECTIVENESS AND REIMBURSEMENT ISSUES IN RENAL-CELL CARCINOMA
    GILEWSKI, T
    VOGELZANG, NJ
    SEMINARS IN ONCOLOGY, 1989, 16 (01) : 20 - 26
  • [5] Cost-effectiveness of sorafenib versus best supportive care in advanced renal cell carcinoma.
    Gao, X.
    Reddy, P.
    Dhanda, R.
    Gondek, K.
    Yeh, Y. C.
    Stadler, W. M.
    Jonasch, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 242S - 242S
  • [6] Cost-effectiveness of sorafenib versus best supportive care in advanced renal cell carcinoma in Spain
    Maroto, P.
    Villavicencio, H.
    Pinol, C.
    Urruticoechea, L.
    VALUE IN HEALTH, 2006, 9 (06) : A280 - A280
  • [7] COST-EFFECTIVENESS OF TREATMENT IN RENAL CELL CARCINOMA ADJUSTED TO THE CLASSIFICATION MODELS
    Sastre-Heres, Alejandro J.
    Iglesias Peinado, Irene
    Ruiz-Sanchez, Daniel
    Garcia Diaz, Benito
    Pena-Diaz, Jaime
    ACTA MEDICA MEDITERRANEA, 2016, 32 (05): : 1689 - 1695
  • [8] Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma in Sweden
    Johal, S.
    Johannesen, K. M.
    Malcolm, B.
    Doan, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [9] COST-EFFECTIVENESS OF SORAFENIB FOR METASTATIC RENAL CELL CARCINOMA: A SYSTEMATIC REVIEW
    Taheri, S.
    Motevalli, M. H.
    Peiravian, F.
    Yousefi, N.
    VALUE IN HEALTH, 2018, 21 : S42 - S42
  • [10] COST-EFFECTIVENESS OF SORAFENIB IN UNRESECTABLE AND/OR METASTATIC RENAL CELL CARCINOMA IN TURKEY
    Tatar, M.
    Akbulut, H.
    VALUE IN HEALTH, 2009, 12 (07) : A222 - A222
12345